|
||||||||||||||||
|
||||||||||||||||
The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy. Page 415 measurement, 201 patient perspectives, 188 relapses, 32 Social Security Administration disability criteria, 401, 402 treatment, 138-140 as side effect, 125, 135, 139 Atrophy, 35, 38, 39, 122, 278, 356 Attention, 118, 154, 200, 403 Autoantigens, 6, 66, 67, 71-74 (passim), 91, 93, 100, 251-255, 257, 279, 280, 354, 355, 357, 398 Autogenous vaccine, 409 Autoimmunity, see Immune response Autologous Blood and Marrow Transplant Registry of North America, 313, 314-315 Autopsies asymptomatic MS, 30 axonal damage and demyelination, 64 brain banks, 316-318, 332, 339 tissue banks, other, 365 Avonex, see Beta-interferon Axons, 3, 7, 20 see also Demyelination; Myelin; Remyelination; Synapses animal models, 95 atrophy, 35, 38, 39 autopsies, 64 degeneration, 58-59, 64, 92, 241-243, 244, 251, 266-267, 278, 280-281, 283, 291, 349, 350, 356 cognitive impairment, 118 electrical impulse conduction, 20, 56, 57, 58, 65, 242, 247, 255, 349, 350 inflammation, 242, 280-281 N-acetyl aspartate, 38, 39-40, 64 magnetic resonance imaging, 35, 38, 39-41, 241 pain, 163 physiology, 54-65, 246; see also “electrical...” supra plasticity, 58, 65, 245, 246-247, 249-251, 291, 349 research recommendations, 65-70, 241-243, 244, 246-247, 249-251, 255, 266-267, 278, 349, 350 secondary progressive MS, 30 T1-weighted hypointense lesions, density measurements, 40 treatment, 243, 278, 280-281, 283, 288, 289, 291, 358 weakness, 136 Azathioprine, 390 BB cells, 6, 395 animal models, 91 autoreactive/demyelinating, 6, 60, 68, 70, 71, 74, 93, 251, 253, 255, 355 cerebrospinal fluid (CSF), 42, 74, 265-266 cloning, 42, 93 biomarkers, 265-266 experimental autoimmune encephalomyelitis (EAE), 93 B lymphocytes, see B cells Back pain, 145, 160, 165 Baclofen, 132-133, 165, 289 Bacteria, 15, 67, 78, 283, 366 Barthel Index, 198, 200, 205, 215 Beck Depression Inventory, 121, 122 Bee venom, 408 Behavioral factors see also Functional status; Patient perspectives patient adherence to therapy, 51-52 measurement, 197 modification therapy, 123, 153 Social Security Administration disability criteria, 403 Bentyl, 144-145 Benzodiazapines, 133, 165 Beta-interferon, 35, 48-51, 60, 277, 284, 298, 307, 361, 392 animal studies, 92 Avonex/Rebif, 49, 50, 388, 396 Betaseron, 49, 51, 53, 388 cognitive impairment, 119 depression, 52, 123, 126-127 neutralizing antibodies, 51, 52, 97 side effects of, 49, 52, 123, 126-127, 388 Biological markers, 42, 44-45, 262-267, 308, 366-367 B cells, 265-266 cerebrospinal fluid (CSF), 30, 41-42 clinical studies, 261, 262 cytokine production, 259, 263-264 demyelination, 44, 45 disease subtypes, 261, 262-267
|
|
|||||||||||||||
